+617.8%
PLTR vs MRNA
-24.9%
+642.7%
-72.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.3% | -3.2% | -2.1% |
| 7D | -10.4% | -13.8% | +3.4% | -8.9% |
| 30D | -20.2% | -17.7% | -2.5% | -18.7% |
| 3M | -12.3% | +14.3% | -26.6% | -14.7% |
| 6M | +13.6% | +336.0% | -322.4% | -19.1% |
| YTD | -13.5% | +575.9% | -589.5% | -47.0% |
| 1Y | -7.1% | +724.4% | -731.5% | -46.4% |
| 3Y | +650.0% | +160.8% | +489.3% | +435.5% |
| 5Y | +617.8% | -24.4% | +642.2% | +564.7% |
| All | +617.8% | -24.9% | +642.7% | +564.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling